2023 World Conference on Lung Cancer (Posters)-EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab

EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab - PDF(Slides)

Back to course

Pdf Summary

A population-based multicenter study was conducted to investigate the incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who received consolidation durvalumab post-chemoradiation. The study aimed to identify clinical predictors, outcomes, and healthcare utilization related to ICI pneumonitis in real-world practice.<br /><br />Using the Alberta Immunotherapy Database, the researchers retrospectively analyzed data from NSCLC patients who received durvalumab in Alberta, Canada from January 2018 to December 2021. Pneumonitis cases were identified based on radiographic changes and clinical assessments by oncologists.<br /><br />The study included a total of 189 patients, with a median duration of durvalumab treatment of 11 months and a median ECOG of 1. The median overall survival (OS) was not reached, with a 1-year survival rate of 64%. The median time-to-treatment failure (TTF) was 11.2 months. Among the patients, 26% developed any grade of pneumonitis, and 9% developed grade 3 pneumonitis.<br /><br />The study found that male gender and pre-existing autoimmune conditions were potential risk factors for developing severe pneumonitis. Pneumonitis development was associated with worse OS and TTF. The burden of healthcare utilization related to pneumonitis was also noted, with a high incidence of corticosteroid use.<br /><br />The authors suggested that larger retrospective studies should be conducted, including different radiological characteristics in the analysis to differentiate between radiation pneumonitis and immune-mediated pneumonitis. They also emphasized the importance of careful patient selection and ongoing monitoring for pneumonitis development.<br /><br />In conclusion, this study reported a higher incidence of severe pneumonitis compared to the PACIFIC trial and highlighted the potential risk factors and outcomes associated with ICI pneumonitis. It also emphasized the need for careful monitoring and management of pneumonitis in LA-NSCLC patients receiving consolidation durvalumab.

Asset Subtitle

Chloe Lim

Meta Tag

Speaker Chloe Lim

Topic Local-Regional NSCLC: Toxicities of Multimodality Therapy

Keywords

immune checkpoint inhibitor pneumonitis

locally advanced non-small cell lung cancer

consolidation durvalumab

clinical predictors

healthcare utilization

radiographic changes

overall survival

risk factors

autoimmune conditions

monitoring